Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Albert Jang, Sree M. Lanka, Hui Ting Ruan, Hamsa L.S. Kumar, Angela Y. Jia, Jorge A. Garcia, Omar Y. Mian & Pedro C. Barata. (2023) Novel therapies for metastatic prostate cancer. Expert Review of Anticancer Therapy 23:12, pages 1251-1263.
Read now
Read now
Maria Teresa Bengoechea-Alonso & Johan Ericsson. (2016) The phosphorylation-dependent regulation of nuclear SREBP1 during mitosis links lipid metabolism and cell growth. Cell Cycle 15:20, pages 2753-2765.
Read now
Read now
Ion Cristóbal, Federico Rojo, Juan Madoz-Gúrpide & Jesús García-Foncillas. (2016) Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications. Molecular and Cellular Biology 36:12, pages 1734-1739.
Read now
Read now
Jie Li, Ruixin Wang, Patrick G. Schweickert, Anju Karki, Yi Yang, Yifan Kong, Nihal Ahmad, Stephen F. Konieczny & Xiaoqi Liu. (2016) Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer. Cell Cycle 15:5, pages 711-719.
Read now
Read now
Articles from other publishers (16)
Hao-Wen Chuang, Jian-Hua Pan, Yi-Xuan Cai, Darius Rupa, Ting-Syuan Huang, Tzu-Chien Kuo, Chiao-Wen Lin, Chi-Wei Chen, Chia-Chin Lin, Herng-Sheng Lee & Ta-Chun Yuan. (2022) Reciprocal regulation of CIP2A and AR expression in prostate cancer cells. Discover Oncology 13:1.
Crossref
Crossref
Fengyi Mao, Yifan Kong, Jinghui Liu, Xiongjian Rao, Chaohao Li, Kristine Donahue, Yanquan Zhang, Katelyn Jones, Qiongsi Zhang, Wei Xu & Xiaoqi Liu. (2022) Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer. The Prostate 82:8, pages 917-932.
Crossref
Crossref
Chelsea E. Cunningham, Mackenzie J. MacAuley, Frederick S. Vizeacoumar, Omar Abuhussein, Andrew Freywald & Franco J. Vizeacoumar. (2020) The CINs of Polo-Like Kinase 1 in Cancer. Cancers 12:10, pages 2953.
Crossref
Crossref
Jieping Hu, Jun Deng, Runfu Cao, Shida Xiong & Ju Guo. (2020) LncRNA GAS5 participates in the regulation of dexamethasone on androgen receptor -negative and -positive prostate cancer cell proliferation. Molecular and Cellular Probes 53, pages 101607.
Crossref
Crossref
Xiangnan Guan, Duanchen Sun, Eric Lu, Joshua A. Urrutia, Robert Evan Reiter, Matthew Rettig, Christopher P. Evans, Primo LaraJrJr, Martin Gleave, Tomasz M. Beer, George V. Thomas, Jiaoti Huang, Rahul R. Aggarwal, David A. Quigley, Adam Foye, William S. Chen, Jack Youngren, Alana S. Weinstein, Joshua M. Stuart, Felix Y. Feng, Eric J. Small, Zheng Xia & Joshi J. Alumkal. (2020) Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research 26:17, pages 4616-4624.
Crossref
Crossref
Sheng-Kai Hsu, Wen-Tsan Chang, I-Ling Lin, Yih-Fung Chen, Nitin Balkrushna Padalwar, Kai-Chun Cheng, Yen-Ni Teng, Chi-Huei Wang & Chien-Chih Chiu. (2020) The Role of Necroptosis in ROS-Mediated Cancer Therapies and Its Promising Applications. Cancers 12:8, pages 2185.
Crossref
Crossref
Chen Shao, Bingbing Yu & Yanan Liu. (2019) Androgen receptor splicing variant 7: Beyond being a constitutively active variant. Life Sciences 234, pages 116768.
Crossref
Crossref
A. Fucic, A. Aghajanyan, Z. Culig & N. Le Novere. (2018) Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer. Pathology & Oncology Research 25:4, pages 1269-1277.
Crossref
Crossref
Sol-Bi Shin, Sang-Uk Woo & Hyungshin Yim. (2019) Cotargeting Plk1 and androgen receptor enhances the therapeutic sensitivity of paclitaxel-resistant prostate cancer. Therapeutic Advances in Medical Oncology 11, pages 175883591984637.
Crossref
Crossref
Lakshmikirupa Sundaresan, Pavitra Kumar & Suvro Chatterjee. (2018) Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer. Future Oncology 14:23, pages 2383-2401.
Crossref
Crossref
Fengyi Mao, Jie Li, Qian Luo, Ruixin Wang, Yifan Kong, Colin Carlock, Zian Liu, Bennet D. Elzey & Xiaoqi Liu. (2018) Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics 17:7, pages 1554-1565.
Crossref
Crossref
Gaelle Rondeau, Parisa Abedinpour, Adrian Chrastina, Jennifer Pelayo, Per Borgstrom & John Welsh. (2018) Differential gene expression induced by anti-cancer agent plumbagin is mediated by androgen receptor in prostate cancer cells. Scientific Reports 8:1.
Crossref
Crossref
Glen J. Weiss, Gayle Jameson, Daniel D. Von Hoff, Barbara Valsasina, Cristina Davite, Claudia Di Giulio, Francesco Fiorentini, Rachele Alzani, Patrizia Carpinelli, Alessandro Di Sanzo, Arturo Galvani, Antonella Isacchi & Ramesh K. Ramanathan. (2017) Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Investigational New Drugs 36:1, pages 85-95.
Crossref
Crossref
Peng Gu, Xu Chen, Ruihui Xie, Jinli Han, Weibin Xie, Bo Wang, Wen Dong, Changhao Chen, Meihua Yang, Junyi Jiang, Ziyue Chen, Jian Huang & Tianxin Lin. (2017) lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. Molecular Therapy 25:8, pages 1959-1973.
Crossref
Crossref
Rosie Elizabeth Ann Gutteridge, Mary Ann Ndiaye, Xiaoqi Liu & Nihal Ahmad. (2016) Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Molecular Cancer Therapeutics 15:7, pages 1427-1435.
Crossref
Crossref
Kathleen A. Fitzgerald, Meenakshi Malhotra, Matt Gooding, Florence Sallas, James C. Evans, Raphael Darcy & Caitriona M. O’Driscoll. (2016) A novel, anisamide-targeted cyclodextrin nanoformulation for siRNA delivery to prostate cancer cells expressing the sigma-1 receptor. International Journal of Pharmaceutics 499:1-2, pages 131-145.
Crossref
Crossref